Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

June 30, 2021 updated by: Bayer

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
823

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Box Hill, Australia, 3128
      • Woolloongabba, Australia, 4102
    • New South Wales
      • St Leonards, New South Wales, Australia, 2065
    • Victoria
      • Clayton, Victoria, Australia, 3168
      • Melbourne, Victoria, Australia, 3052
      • Prahran, Victoria, Australia, 3181
      • Reservoir, Victoria, Australia, 3073
  • Austria
      • Graz, Austria, 3086
      • Innsbruck, Austria, 6020
      • Salzburg, Austria, 5020
      • Salzburg, Austria, 5026
      • St. Pölten, Austria, 3100
      • Wien, Austria, 1130
  • Bulgaria
      • Haskovo, Bulgaria, 6300
      • Lukovit, Bulgaria, 5770
      • Plovdiv, Bulgaria, 4002
      • Ruse, Bulgaria, 7003
      • Sofia, Bulgaria, 1431
      • Stara Zagora, Bulgaria, 6000
      • Varna, Bulgaria, 9010
      • Varna, Bulgaria, 9000
  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1L8
      • Vancouver, British Columbia, Canada, V6E 1M7
    • Ontario
      • Courtice, Ontario, Canada, L1E 3C3
      • Kitchener, Ontario, Canada, N2H 5Z8
      • Scarborough, Ontario, Canada, M1H 3G4
      • Toronto, Ontario, Canada, M4N 3M5
      • Toronto, Ontario, Canada, M4C 5T2
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
  • Czechia
      • Chrudim, Czechia, 537 01
      • Koprivnice, Czechia, 742 21
      • Krnov, Czechia, 794 01
      • Praha 2, Czechia, 12808
  • Denmark
      • Aarhus C, Denmark, 8000
      • Gentofte, Denmark, 2820
      • Herlev, Denmark, 2730
      • Hillerød, Denmark, DK-3400
      • Holbaek, Denmark, 4300
      • Holstebro, Denmark, DK-7500
      • Kolding, Denmark, 6000
  • Finland
      • Helsinki, Finland, 00180
      • Jyväskylä, Finland, 40620
      • Oulu, Finland, 90100
      • Tampere, Finland, 33520
      • Turku, Finland, 20520
  • France
      • Amiens, France, 80000
      • La Tronche, France, 38700
      • Lyon Cedex, France, 69437
      • Paris Cedex 15, France, 75908
      • Strasbourg, France, 67091
  • Germany
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30625
    • Nordrhein-Westfalen
      • Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32545
      • Düsseldorf, Nordrhein-Westfalen, Germany, 40210
    • Rheinland-Pfalz
      • Ludwigshafen, Rheinland-Pfalz, Germany, 67059
      • Neuwied, Rheinland-Pfalz, Germany, 56564
  • Hong Kong
      • Hong Kong, Hong Kong
      • Shatin, Hong Kong
  • Hungary
      • Budapest, Hungary, 1085
      • Debrecen, Hungary, 4032
      • Eger, Hungary, 3300
      • Nagykanizsa, Hungary, 8800
      • Papa, Hungary, 8500
  • Israel
      • Ashkelon, Israel, 7830604
      • Holon, Israel, 5822012
      • Jerusalem, Israel, 9112001
      • Kfar Saba, Israel, 4428164
      • Petach Tikva, Israel, 4941492
      • Tel Aviv, Israel, 6203854
      • Tel Aviv, Israel, 6937947
  • Italy
    • Campania
      • Napoli, Campania, Italy, 80131
    • Lombardia
      • Bergamo, Lombardia, Italy, 24127
      • Bergamo, Lombardia, Italy, 24020
      • Milano, Lombardia, Italy, 20157
      • Milano, Lombardia, Italy, 20134
      • Monza-Brianza, Lombardia, Italy, 20832
    • Puglia
      • Foggia, Puglia, Italy, 71013
    • Sardegna
      • Cagliari, Sardegna, Italy, 09134
    • Toscana
      • Pisa, Toscana, Italy, 56124
    • Veneto
      • Padova, Veneto, Italy, 35128
  • Korea, Republic of
      • Busan, Korea, Republic of, 49241
      • Seoul, Korea, Republic of, 03722
      • Seoul, Korea, Republic of, 06591
  • Netherlands
      • AlMERE, Netherlands, 1311 RL
      • Eindhoven, Netherlands, 5600 PD
      • Groningen, Netherlands, 9713 GZ
      • Hoogeveen, Netherlands, 7909 AA
      • Maastricht, Netherlands, 6229 HX
  • Norway
      • Hamar, Norway, 2326
      • Ålesund, Norway, 6026
  • Poland
      • Bialystok, Poland, 15-276
      • Bydgoszcz, Poland, 85-822
      • Lodz, Poland, 90-153
      • Lublin, Poland, 20-081
      • Olawa, Poland, 55-200
      • Warszawa, Poland
      • Wroclaw, Poland, 51-162
  • Portugal
      • Almada, Portugal, 2801-951
      • Lisboa, Portugal, 1069-166
      • Lisboa, Portugal, 1449-005
  • South Africa
    • Gauteng
      • Klipsruit West, Gauteng, South Africa, 1812
      • Krugersdorp, Gauteng, South Africa, 1739
      • Lenasia South, Gauteng, South Africa, 1829
      • Newtown, Gauteng, South Africa, 2113
    • KwaZulu Natal
      • Durban, KwaZulu Natal, South Africa, 4091
      • Durban, KwaZulu Natal, South Africa, 4037
    • Kwazulu-Natal
      • Durban, Kwazulu-Natal, South Africa, 4067
      • Merebank, Kwazulu-Natal, South Africa, 4052
      • Tongaat, Kwazulu-Natal, South Africa, 4400
    • Western Cape
      • Cape Town, Western Cape, South Africa, 7570
      • Goodwood, Western Cape, South Africa, 7460
      • Somerset West, Western Cape, South Africa, 7130
      • Worcester, Western Cape, South Africa, 6850
  • Spain
      • Barcelona, Spain, 08025
      • Girona, Spain, 17007
      • Madrid, Spain, 28034
      • Madrid, Spain, 28041
    • A Coruña
      • Ferrol, A Coruña, Spain, 15405
    • Cádiz
      • Jerez de la Frontera, Cádiz, Spain, 11407
    • Valencia
      • Sagunto, Valencia, Spain, 46520
  • Sweden
      • Karlstad, Sweden, 651 85
      • Kristianstad, Sweden, 29185
      • Skövde, Sweden, 541 85
      • Stockholm, Sweden, 141 86
      • Stockholm, Sweden, 113 24
      • Stockholm, Sweden, 111 57
      • Uppsala, Sweden, 753 19
      • Vällingby, Sweden, 162 68
      • Örebro, Sweden, 701 85
  • Taiwan
      • Kaohsiung, Taiwan, 833
      • Taipei, Taiwan, 11217
      • Taipei, Taiwan, 110
      • Taipei, Taiwan, 10002
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
    • California
      • Chula Vista, California, United States, 91910
      • Los Angeles, California, United States, 90022
      • Los Gatos, California, United States, 95032
    • Connecticut
      • New Haven, Connecticut, United States, 06510
    • Florida
      • Miami, Florida, United States, 33015
      • Pembroke Pines, Florida, United States, 33028
    • Illinois
      • Chicago, Illinois, United States, 60611
      • Chicago, Illinois, United States, 60612
    • Michigan
      • Flint, Michigan, United States, 48504
    • New York
      • Flushing, New York, United States, 11355
    • South Carolina
      • Orangeburg, South Carolina, United States, 29118
    • Tennessee
      • Chattanooga, Tennessee, United States, 37408
    • Texas
      • Dallas, Texas, United States, 75235-3858
    • Vermont
      • Burlington, Vermont, United States, 05401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women aged 18 years and older.The lower age limit may be higher if legally required in the participating country
  • Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active.

  • Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria

    • are on oral antidiabetics and / or insulin,
    • have a documented fasting glucose >/= 7.0 mmol/L in the medical history,
    • have a 2 hour plasma glucose >/=11.1 mmol/L during an oral glucose tolerance test in the medical history, or
    • have a glycated hemoglobin (HbA1c) >/=6.5% [National Glycohemoglobin Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)] in the medical history or at the run-in visit

  • Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria:

    • Persistent very high albuminuria defined as urinary albumin-to-creatine ratio (UACR) of >/=300 mg/g ( >/= 34 mg/mmol) in 2 out of 3 first morning void samples and estimated glomerular filtration rate (eGFR) >/=30 mL/min/1.73 m² but < 90 mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL = milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or
    • Persistent high albuminuria defined as UACR of >/=30 mg/g but <300 mg/g in (>/=3.4mg/mmol but <34 mg/mmol) in 2 out of 3 first morning void samples and eGFR >/=30 mL/min/1.73 m² but < 90 mL/min/1.73m²
  • Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit
  • Serum potassium </= 4.8 mmol/L at both the run-in visit and the screening visit

Exclusion Criteria:

  • Non-diabetic renal disease
  • Glycated hemoglobin (HbA1c) >12% at the run-in visit or the screening visit
  • UACR >3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the run-in visit or screening visit
  • Hypertension with mean sitting systolic blood pressure (SBP) >/=180 mmHg or mean sitting diastolic blood pressure (DBP) >/=110 mmHg at the run-in visit or mean supine SBP >/=160 mmHg or mean sitting DBP >/=100 mmHg at the screening visit
  • Subjects with a clinical diagnosis of heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the run-in visit
  • Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic
  • Dialysis for acute renal failure within the previous 6 months prior to the run-in visit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Finerenone (BAY94-8862) (1.25 mg)
1.25 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862)(2.5 mg)
2.5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862)(5 mg)
5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862)(7.5 mg)
7.5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862) (10 mg)
10 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862) (15 mg)
15 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
EXPERIMENTAL: Finerenone (BAY94-8862)(20 mg)
20 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
PLACEBO_COMPARATOR: Placebo
Placebo oral dose once daily for 90 days
Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Ratio of UACR at Day 90 to UACR at Baseline
Time Frame: Baseline and Day 90±2
Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.
Baseline and Day 90±2

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline to Day 90 in Serum Potassium
Time Frame: Baseline and Day 90±2
Baseline and Day 90±2
Change From Baseline to Day 90 in eGFR
Time Frame: Baseline and Day 90±2
An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Baseline and Day 90±2
Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)
Time Frame: Baseline and Day 90±2
The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" subscore was analyzed.
Baseline and Day 90±2
Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)
Time Frame: Baseline and Day 90±2
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).
Baseline and Day 90±2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bayer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 12, 2013

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 9, 2014

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 7, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 7, 2013

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 7, 2013

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2013

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 1, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 30, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 16243
  • 2012-004179-38 (EUDRACT_NUMBER)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings